SVB Wealth LLC Takes Position in Hologic, Inc. (NASDAQ:HOLX)

SVB Wealth LLC acquired a new position in shares of Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 13,165 shares of the medical equipment provider’s stock, valued at approximately $949,000.

Other large investors have also recently added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after purchasing an additional 2,174,093 shares during the last quarter. Nordea Investment Management AB grew its stake in Hologic by 32.7% during the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after buying an additional 544,889 shares during the last quarter. Swedbank AB grew its stake in Hologic by 18.8% during the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after buying an additional 306,562 shares during the last quarter. JPMorgan Chase & Co. increased its position in Hologic by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock worth $110,700,000 after buying an additional 238,222 shares during the period. Finally, Barclays PLC lifted its stake in Hologic by 47.6% in the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock valued at $58,507,000 after buying an additional 231,578 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on HOLX shares. Mizuho lowered their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Raymond James restated an “outperform” rating and issued a $90.00 target price (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Stephens reaffirmed an “overweight” rating and set a $84.00 price target on shares of Hologic in a report on Thursday, February 6th. William Blair reiterated an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Finally, Leerink Partners cut Hologic from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Hologic has an average rating of “Hold” and a consensus price target of $85.77.

Hologic Stock Down 0.2 %

Shares of Hologic stock opened at $63.27 on Tuesday. Hologic, Inc. has a 12-month low of $62.69 and a 12-month high of $84.67. The firm has a market capitalization of $14.20 billion, a PE ratio of 19.96, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The stock’s fifty day moving average is $68.98 and its 200-day moving average is $75.78.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Activity at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 1.88% of the stock is owned by insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.